Extend your dog’s vitality — and help others too
Our study explores a gene therapy that could reduce arthritis symptoms and preserve mobility in aging dogs. Your companion may benefit — and contribute to research that helps countless others.






FAQs
The follistatin therapy has been tested in human clinical trials with no serious adverse events. All procedures follow strict veterinary safety protocols.
The study will be conducted in The United States, in partnership with veterinary clinics in the San Francisco, Los Angeles, New York, Boston, and Orlando regions.
Dogs experiencing age-related changes including arthritis, reduced mobility, or other degenerative conditions may be eligible.
We're currently finalizing regulatory approvals. Pre-registered participants will be notified first when enrollment opens.
The core study lasts 12 months, with optional extended follow-up. Participants receive comprehensive veterinary care and monitoring throughout.
No, participants are not paid for joining the study. However, those who complete the trial with no more than one missed appointment may receive tokens. These tokens don’t have cash value, but they do give you a voice in how your dog’s data is used, ensuring you remain part of the decision-making process.